These activities are expected to remain intact when antibodies against PD-1 are used to block the immune suppressive activities of the PD-L1/PD-1 axis, because the pro-cancer functions of PD-L1 would remain untouched by the treatment and would continue fueling the pro-metastatic activities of the cancer cells. The gene discussed is CD274; the disease is cancer.